A sweeping review of decades of research has cast significant doubt on the widely held belief that medicinal cannabis effectively treats most mental health and substance use disorders. Researchers meticulously examined data from 54 randomized controlled trials, spanning from 1980 to 2025, focusing on cannabinoids as the primary form of treatment.
The analysis, involving nearly 2,500 participants, revealed a concerning trend: cannabis-based treatments were “rarely justified” for routine use. In fact, the risk of experiencing adverse side effects was a startling 75% higher in those receiving cannabinoid treatment.
Despite the increasing prevalence of cannabis prescriptions for conditions like depression, anxiety, and PTSD in countries like the U.S., U.K., and Australia, the study found “no evidence to suggest they are effective” for these ailments. This challenges current practices and raises questions about the rationale behind widespread medicinal cannabis approvals.
While a few areas showed limited promise – including potential benefits for cannabis use disorder, insomnia, and certain neurological symptoms – the quality of evidence remained low. Crucially, cannabinoids offered no significant relief for anxiety disorders, psychotic disorders, PTSD, opioid use disorder, or anorexia nervosa.
The research highlighted a critical gap in understanding cannabis’s impact on conditions like ADHD, bipolar disorder, and OCD, as sufficient data for analysis was simply unavailable. Even for depression, no trials met the rigorous standards required for inclusion in the review.
Experts warn that relying on medicinal cannabis for mental health could inadvertently worsen outcomes. Delaying access to proven treatments, and potentially increasing the risk of psychosis or developing cannabis dependence, are serious concerns.
It’s important to note that the study doesn’t dismiss cannabis’s medical value entirely. Established benefits exist for conditions like epilepsy, multiple sclerosis, and certain types of chronic pain. However, the findings strongly suggest a disconnect between these established uses and the growing trend of prescribing cannabis for mental health.
This comprehensive review surpasses previous studies, which often relied on smaller sample sizes and synthetic cannabinoids that don’t reflect the potency and composition of products available today. It represents the most thorough evaluation to date of cannabis specifically for anxiety, depression, and PTSD.
Mental health professionals emphasize the importance of self-monitoring for anyone using cannabis, paying close attention to changes in mood, sleep, concentration, and social engagement. Increased paranoia, a need for higher doses, or a feeling of mental fogginess should serve as warning signs.
Underlying issues may be masked by cannabis use, delaying individuals from seeking and receiving effective, evidence-based care. Prioritizing mental health with proven methods – therapy, coaching, meditation, and self-care – is crucial.
The study acknowledges limitations, including a high risk of bias in nearly half of the reviewed studies. Variations in product types, dosages, and patient groups further complicate the interpretation of results. Real-world cannabis use, often involving higher doses and combinations with other substances, differs significantly from controlled clinical trial settings.
